Metabolic Switch in the Tumor Microenvironment Determines Immune Responses to Anti-cancer Therapy
Tumor-induced immune tolerance permits growth and spread of malignant cells. Cancer cells have strong influence on surrounding cells and shape the hypoxic tumor microenvironment (TME) facilitating cancer progression. A dynamic change in glucose metabolism occurring in cancer cells and its influence...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2018-08-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fonc.2018.00284/full |
| _version_ | 1819097911305175040 |
|---|---|
| author | Barbara Wegiel Barbara Wegiel Marta Vuerich Saeed Daneshmandi Pankaj Seth Pankaj Seth Pankaj Seth |
| author_facet | Barbara Wegiel Barbara Wegiel Marta Vuerich Saeed Daneshmandi Pankaj Seth Pankaj Seth Pankaj Seth |
| author_sort | Barbara Wegiel |
| collection | DOAJ |
| description | Tumor-induced immune tolerance permits growth and spread of malignant cells. Cancer cells have strong influence on surrounding cells and shape the hypoxic tumor microenvironment (TME) facilitating cancer progression. A dynamic change in glucose metabolism occurring in cancer cells and its influence on the TME are still poorly understood. Indeed, cancer and/or immune cells undergo rapid adaptation in metabolic pathways during cancer progression. Metabolic reprograming affects macrophages, T cells, and myeloid derived suppressor cells (MDSCs) among other immune cells. Their role in the TME depends on a nature and concentration of factors, such as cytokines, reactive oxygen species (ROS), growth factors, and most importantly, diffusible metabolites (i.e., lactate). Further, the amounts of available nutrients and oxygen as well as activity of microbiota may influence metabolic pathways in the TME. The roles of metabolites in regulating of the interaction between immune and cancer cell are highlighted in this review. Targeting metabolic reprogramming or signaling pathways controlling cell metabolism in the TME might be a potential strategy for anti-cancer therapy alone or in combination with current immunotherapies. |
| first_indexed | 2024-12-22T00:22:37Z |
| format | Article |
| id | doaj.art-fa88f7df2c8b4d15963f9f9d1024c752 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-22T00:22:37Z |
| publishDate | 2018-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-fa88f7df2c8b4d15963f9f9d1024c7522022-12-21T18:45:07ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2018-08-01810.3389/fonc.2018.00284368714Metabolic Switch in the Tumor Microenvironment Determines Immune Responses to Anti-cancer TherapyBarbara Wegiel0Barbara Wegiel1Marta Vuerich2Saeed Daneshmandi3Pankaj Seth4Pankaj Seth5Pankaj Seth6Department of Surgery, Beth Israel Deaconess Medical Center, Boston, MA, United StatesCancer Research Institute, Beth Israel Deaconess Medical Center, Boston, MA, United StatesDivision of Interdisciplinary Medicine, Beth Israel Deaconess Medical Center, Boston, MA, United StatesDivision of Interdisciplinary Medicine, Beth Israel Deaconess Medical Center, Boston, MA, United StatesCancer Research Institute, Beth Israel Deaconess Medical Center, Boston, MA, United StatesDivision of Interdisciplinary Medicine, Beth Israel Deaconess Medical Center, Boston, MA, United StatesDepartment of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, United StatesTumor-induced immune tolerance permits growth and spread of malignant cells. Cancer cells have strong influence on surrounding cells and shape the hypoxic tumor microenvironment (TME) facilitating cancer progression. A dynamic change in glucose metabolism occurring in cancer cells and its influence on the TME are still poorly understood. Indeed, cancer and/or immune cells undergo rapid adaptation in metabolic pathways during cancer progression. Metabolic reprograming affects macrophages, T cells, and myeloid derived suppressor cells (MDSCs) among other immune cells. Their role in the TME depends on a nature and concentration of factors, such as cytokines, reactive oxygen species (ROS), growth factors, and most importantly, diffusible metabolites (i.e., lactate). Further, the amounts of available nutrients and oxygen as well as activity of microbiota may influence metabolic pathways in the TME. The roles of metabolites in regulating of the interaction between immune and cancer cell are highlighted in this review. Targeting metabolic reprogramming or signaling pathways controlling cell metabolism in the TME might be a potential strategy for anti-cancer therapy alone or in combination with current immunotherapies.https://www.frontiersin.org/article/10.3389/fonc.2018.00284/fulltumor microenvironment (TME)metabolic reprogrammingimmune stromaHIF-1αlactate |
| spellingShingle | Barbara Wegiel Barbara Wegiel Marta Vuerich Saeed Daneshmandi Pankaj Seth Pankaj Seth Pankaj Seth Metabolic Switch in the Tumor Microenvironment Determines Immune Responses to Anti-cancer Therapy Frontiers in Oncology tumor microenvironment (TME) metabolic reprogramming immune stroma HIF-1α lactate |
| title | Metabolic Switch in the Tumor Microenvironment Determines Immune Responses to Anti-cancer Therapy |
| title_full | Metabolic Switch in the Tumor Microenvironment Determines Immune Responses to Anti-cancer Therapy |
| title_fullStr | Metabolic Switch in the Tumor Microenvironment Determines Immune Responses to Anti-cancer Therapy |
| title_full_unstemmed | Metabolic Switch in the Tumor Microenvironment Determines Immune Responses to Anti-cancer Therapy |
| title_short | Metabolic Switch in the Tumor Microenvironment Determines Immune Responses to Anti-cancer Therapy |
| title_sort | metabolic switch in the tumor microenvironment determines immune responses to anti cancer therapy |
| topic | tumor microenvironment (TME) metabolic reprogramming immune stroma HIF-1α lactate |
| url | https://www.frontiersin.org/article/10.3389/fonc.2018.00284/full |
| work_keys_str_mv | AT barbarawegiel metabolicswitchinthetumormicroenvironmentdeterminesimmuneresponsestoanticancertherapy AT barbarawegiel metabolicswitchinthetumormicroenvironmentdeterminesimmuneresponsestoanticancertherapy AT martavuerich metabolicswitchinthetumormicroenvironmentdeterminesimmuneresponsestoanticancertherapy AT saeeddaneshmandi metabolicswitchinthetumormicroenvironmentdeterminesimmuneresponsestoanticancertherapy AT pankajseth metabolicswitchinthetumormicroenvironmentdeterminesimmuneresponsestoanticancertherapy AT pankajseth metabolicswitchinthetumormicroenvironmentdeterminesimmuneresponsestoanticancertherapy AT pankajseth metabolicswitchinthetumormicroenvironmentdeterminesimmuneresponsestoanticancertherapy |